134 results
Page 2 of 7
8-K
EX-10.1
u99akmw3fuk8 beszju0
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
4ifkcrid8l
14 Feb 24
Other Events
4:11pm
424B5
b41jpti xgq
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
dch36ifos7crbn
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.2
qyu4a6n
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
EX-4.4
hsfn9z 9th4cxegs1bt
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
EX-4.3
y0rwk
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
EX-4.8
k4jhymhk mz3lqn8
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
EX-4.9
r6m9ji81
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
EX-4.7
i8ogjhak
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
zdw8rrmlz0wy
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
rm3rff
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-10.1
l8gxzvaq9ihr
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
S-8
EX-99.4
f71tb5
2 Feb 24
Registration of securities for employees
4:04pm
8-K
EX-10.2
bf1semaxukn5mlkyhxbi
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K
EX-10.1
n59qpywz6gzmmsnnk
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K/A
EX-99.1
mkypq 5bc
22 Nov 23
Report of Independent Auditors
4:02pm